Chinese biopharmaceutical company Beijing Mabworks Biotech Co.,Ltd announced the completion of its Series C1 and C2 rounds of funding at 1.13 billion yuan ($160 million), according to an announcement.
Continue reading this premium story with a subscription to DealStreetAsia.
SubscribeAlready a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
